Cable Hill Partners, LLC Corvus Pharmaceuticals, Inc. Transaction History

Cable Hill Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$8.58 - $11.4 $2,145 - $2,850	-250 Closed	0 $0
Q2 2018 Aug 03, 2018	SELL	$9.42 - $13.73 $7,065 - $10,297	-750 Reduced 75.0%	250 $3,000
Q1 2018 Apr 20, 2018	BUY	$7.48 - $11.53 $7,480 - $11,530	1,000 New	1,000 $10,000
Q4 2017 Feb 22, 2018	SELL	$9.3 - $16.93 $7,440 - $13,544	-800 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	800	800 $10,000

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $223M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Cable Hill Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Cable Hill Partners, LLC with notifications on news.